Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.
Last trade$2.25
Day change-$0.045 (-1.97%)
Day range$2.13 – $2.36
Volume15,689
Market cap$3M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.56M
Price / earnings
—
Price / book
0.34×
Price / sales
—
EV / sales
—
EV / EBITDA
0.63×
Profitability
Earnings per share
-$6.88
Return on assets
-82.02%
Return on equity
-103.28%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.91×
Quick ratio
3.91×
Cash ratio
3.83×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$7.08M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BJDX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$944.85K
$911.32K
$1.13M
$875.6K
$831.34K
$1.1M
$1.1M
$930.65K
Research and development
$1.12M
$1.44M
$811.84K
$586.14K
$785.61K
$889.9K
$784.8K
$554K
Total operating expenses
$2.06M
$2.35M
$1.94M
$1.46M
$1.62M
$1.99M
$1.89M
$1.48M
Operating income
-$2.06M
-$2.35M
-$1.94M
-$1.46M
-$1.62M
-$1.99M
-$1.89M
-$1.48M
Interest expense
$0
$0
$0
-$187
$0
$0
$0
-$729
Income before taxes
-$2.01M
-$2.32M
-$1.92M
-$1.43M
-$1.6M
-$1.96M
-$1.86M
-$1.43M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$2.01M
-$2.32M
-$1.92M
-$1.43M
-$1.6M
-$1.96M
-$1.86M
-$1.43M
Net income attributable to common shareholders
-$2.01M
-$2.32M
-$1.92M
-$1.43M
-$1.6M
-$1.96M
-$1.86M
-$1.43M
EBITDA
-$2M
-$2.32M
-$1.91M
-$1.43M
-$1.61M
-$1.97M
-$1.87M
-$1.46M
Basic earnings per share
-$1.72
-$4.48
-$7.80
-$6.13
-$16.92
-$22.56
-$53.84
-$43.49
Diluted earnings per share
-$1.72
-$4.48
-$7.80
-$6.13
-$16.92
-$22.56
-$53.84
-$43.49
Recent news
Company coverage with links to the original publishers.
Bluejay Diagnostics closed a private placement raising $8.5 million upfront with up to $15.2 million in potential additional proceeds from warrant exercises. The company plans to use net proceeds for FDA approval efforts, R&D activities, and working capital, with cash runway expected to extend into Q1 2027 and potentially beyond FDA approval if warrants are fully exercised.
Bluejay Diagnostics (BJDX) shares traded down 1.84% on Wednesday despite positive developments. The company announced a private placement raising up to $23.6 million ($8.5M upfront plus $15.1M from warrant exercises) to extend cash runway into early 2027 ahead of FDA submission. The company also partnered with Argonaut Manufacturing Services to establish U.S.-based manufacturing capabilities for its Symphony sepsis testing platform. While the stock showed strong momentum (77.52 score), the recent price action suggests caution as it approaches overbought conditions.
Bluejay Diagnostics, Inc. announced that an abstract related to its Symphony IL-6 Test has been accepted for presentation at the 2025 SAEM Annual Meeting. The presentation will focus on results from the SYMON-I pilot clinical study, which evaluated IL-6 as a prognosticator for sepsis patients.
ACTON, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $8.75 million, before deducting underwriting discounts and other estimated expenses payable by the Company. The base offering consisted of 5,368,098 Common Units or Prefunded Units, each Unit consisting of one share of the Company’s common stock (“Common Stock”) or one pre-funded warrant to purchase one share of Common Stock (each, a “Prefunded Warrant”), two Class C warrants each to purchase one share of our common stock (each, a “Class C Warrant”) and one Class D Warrant to purchase such number of shares of common stock as determined in the Class D Warrant (each, a “Class D Warrant” and together with the Class C Warrants, the “Common Warrants”). The purchase price of each Common Unit is $1.63, and the purchase price of each Prefunded Unit is $1.6299 (which is equal to the public offering price per Common Unit minus $0.0001). The Prefunded Warrants will be immediately exercisable and may be exercised at any time until all the Prefunded Warrants are exercised in full.
Results from primary analysis of the SYMON-I pilot clinical study consistent with IL-6 as a predictor of patients who have a mortality event with 28 days after sepsis and septic shock diagnosis and are admitted to the intensive care unit (ICU). Results from primary analysis of the SYMON-I pilot clinical study consistent with IL-6 as a predictor of patients who have a mortality event with 28 days after sepsis and septic shock diagnosis and are admitted to the intensive care unit (ICU).
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.